Sign in Subscribe
COVID-19

Hybrid Vaccine Design Offers New Hope Against Influenza A Virus and SARS-CoV-2

Strategic Insights

— 1 min read

Researchers have developed a new approach to vaccine design that could provide effective protection against both Influenza A Virus and SARS-CoV-2. The study, published in Human Immunology, employed a bioinformatic approach to design a hybrid vaccine based on the epitopes of both viruses. This innovative method has the potential to induce long-lasting innate and adaptive immune responses, providing a safer and more effective defense against these viruses.

Key Takeaways:

  • The study, conducted by researchers at Shiraz University of Medical Sciences, developed a hybrid vaccine design that combines the epitopes of Influenza A Virus and SARS-CoV-2 to create a more effective and safe vaccine.
  • The selected peptides demonstrated a potentially effective immune response and showed promise as safe and suitable for hybrid vaccine design.
  • The vaccine design focused on epitopes that are conserved against mutations and are safe in terms of toxicity and allergenicity.
  • The study concluded that hybrid vaccine design using this approach could lead to next-generation hybrid vaccines that help establish a more consistent defense against both viruses.

Statistics:

  • 86.6% of the selected peptides demonstrated a potentially effective immune response (One Action and Multiple Results: Influenza A Virus and SARS-CoV-2 Poly-Epitope-Based Hybrid Vaccine Exploration by Reverse Vaccinology and Immunoinformatic Methods).
  • 75% of the epitopes selected were confirmed to induce robust humoral and cell-mediated immunity.
  • The study focused on the epitopes' binding quality to cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B cell, which were confirmed using sequence-based prediction methods.

Sources:

  • NewsRx LLC. Reports on Influenza A Virus Findings from Shiraz University of Medical Sciences Provide New Insights. Medical Letter on the CDC & FDA. October 26, 2025; p 654.
  • One Action and Multiple Results: Influenza A Virus and SARS-CoV-2 Poly-Epitope-Based Hybrid Vaccine Exploration by Reverse Vaccinology and Immunoinformatic Methods. Human Immunology. 2025;86(6):111588.
  • Elsevier Science Inc. 230 Park Ave, Ste 800, New York, NY 10169, USA.

Read more